Table 1.
General characteristics of patients with chronic hepatitis C included in the study (total) and split according to the presence of hepatic steatosis, n (%).
| Characteristic | Hepatic steatosis | Total | |
|---|---|---|---|
| No, n (%) | Yes, n (%) | n (%) | |
| n | 111 (47.0) | 125 (53.0) | 236 (100) |
| Sex | |||
| Male | 56 (54.4) | 47 (45.6) | 103 (43.6) |
| Female | 55 (41.4) | 78 (58.6) | 133 (56.4) |
| Age | |||
| < 50 years | 40 (58.8) | 28 (41.2) | 68 (28.8) |
| ≥ 50 years | 71 (42.3) | 97 (57.7) | 168 (71.2) |
| BMI | |||
| < 25 kg/m2 | 45 (48.9) | 47 (51.1) | 92 (39.8) |
| ≥ 25 kg/m2 | 64 (46.0) | 75 (54.0) | 139 (60.2) |
| Ethnicity | |||
| White | 85 (44.5) | 106 (55.5) | 191 (81.2) |
| No White | 25 (56.8) | 19 (43.2) | 44 (18.8) |
| HOMA-IR | |||
| < 3 | 80 (52.6) | 72 (47.4) | 152 (65.5) |
| ≥ 3 | 30 (37.5) | 50 (62.5) | 80 (34.5) |
| Alcohol consumption | |||
| < 20 g/day | 73 (49.3) | 75 (50.7) | 148 (62.7) |
| ≥ 20 g/day | 38 (43.1) | 50 (56.9) | 88 (37.3) |
| Hypertension | |||
| No | 76 (50.7) | 74 (49.3) | 150 (63.6) |
| Yes | 35 (40.7) | 51 (59.3) | 86 (36.4) |
| Diabetes mellitus | |||
| No | 95 (47.5) | 105 (52.5) | 200 (84.7) |
| Yes | 16 (44.4) | 20 (55.6) | 36 (15.3) |
| HCV genotype 3 | |||
| No | 99 (51.3) | 94 (48.7) | 193 (81.8) |
| Yes | 12 (27.9) | 31 (72.1) | 43 (18.2) |
| HCV viral load | |||
| < 850,000 IU/mL | 42 (45.2) | 52 (54.2) | 94 (41.2) |
| ≥ 850,000 IU/mL | 64 (47.8) | 70 (52.2) | 134 (58.8) |
| ALT | |||
| < 41 U/L | 54 (54.0) | 46 (46.0) | 100 (42.4) |
| ≥ 41 U/L | 57 (41.9) | 79 (58.1) | 136 (57.6) |
| AST | |||
| < 37 U/L | 67 (58.3) | 48 (41.7) | 115 (48.7) |
| ≥ 37 U/L | 44 (36.4) | 77 (63.6) | 121 (51.3) |
| GGT | |||
| 8‒61 U/L | 70 (53.0) | 62 (47.0) | 132 (55.9) |
| > 61 U/L | 41 (39.4) | 63 (60.6) | 104 (44.1) |
| Total cholesterol | |||
| < 200 mg/dL | 84 (46.7) | 96 (53.3) | 180 (76.3) |
| ≥ 200 mg/dL | 27 (48.2) | 29 (51.8) | 56 (23.7) |
| LDL | |||
| < 130 mg/dL | 91 (46.0) | 107 (54.0) | 198 (83.9) |
| ≥ 130 mg/dL | 20 (52.6) | 18 (47.4) | 38 (16.1) |
| HDL | |||
| > 60 mg/dL | 33 (44.0) | 42 (56.0) | 75 (31.8) |
| ≤ 60 mg/dL | 78 (48.4) | 83 (51.6) | 161 (68.2) |
| VLDL | |||
| < 40 mg/dL | 104 (47.3) | 116 (52.7) | 220 (93.2) |
| ≥ 40 mg/dL | 7 (43.8) | 9 (56.3) | 16 (6.8) |
| Triglyceride | |||
| < 200 mg/dL | 104 (47.1) | 117 (52.9) | 221 (93.6) |
| ≥ 200 mg/dL | 7 (46.7) | 8 (53.3) | 15 (6.4) |
| Hepatic fibrosis | |||
| F0‒F2 | 97 (51.9) | 90 (48.1) | 187 (79.2) |
| F3‒F4 | 14 (28.6) | 35 (71.4) | 49 (20.8) |
| Hepatic inflammatory activity | |||
| A0‒A1 | 57 (71.3) | 23 (28.8) | 80 (33.9) |
| A2‒A3 | 54 (34.6) | 102 (65.4) | 156 (66.1) |
| Hepatic siderosis | |||
| No | 106 (48.0) | 115 (52.0) | 221 (93.6) |
| Yes | 5 (33.3) | 10 (66.7) | 15 (6.4) |
| Metabolic syndrome | |||
| No | 111 (47.5%) | 123 (52.5%) | 234 (99.1%) |
| Yes | 0 (0.0%) | 2 (100.0%) | 2 (0.9%) |
ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; BMI, Body Mass Index; CI, Confidence Interval; GGT, Gamma Glutamyl Transpeptidase; HCV, Hepatitis C Virus; HDL, High-Density Lipoprotein; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; LDL, Low-Density Lipoprotein; OR, Odds Ratio; VLDL, Very Low-Density Lipoprotein.